CO2020013468A2 - Agentes de unión a c3 y métodos para su uso - Google Patents
Agentes de unión a c3 y métodos para su usoInfo
- Publication number
- CO2020013468A2 CO2020013468A2 CONC2020/0013468A CO2020013468A CO2020013468A2 CO 2020013468 A2 CO2020013468 A2 CO 2020013468A2 CO 2020013468 A CO2020013468 A CO 2020013468A CO 2020013468 A2 CO2020013468 A2 CO 2020013468A2
- Authority
- CO
- Colombia
- Prior art keywords
- binding agents
- methods
- encode
- antibodies
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652253P | 2018-04-03 | 2018-04-03 | |
| PCT/US2019/025123 WO2019195136A1 (en) | 2018-04-03 | 2019-04-01 | C3-binding agents and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020013468A2 true CO2020013468A2 (es) | 2020-11-10 |
Family
ID=66630340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0013468A CO2020013468A2 (es) | 2018-04-03 | 2020-10-26 | Agentes de unión a c3 y métodos para su uso |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11136381B2 (enExample) |
| EP (1) | EP3790897A1 (enExample) |
| JP (2) | JP7477457B2 (enExample) |
| KR (1) | KR20200138290A (enExample) |
| CN (1) | CN112105638A (enExample) |
| AR (1) | AR117565A1 (enExample) |
| AU (1) | AU2019248557A1 (enExample) |
| BR (1) | BR112020019907A2 (enExample) |
| CA (1) | CA3093356A1 (enExample) |
| CL (2) | CL2020002522A1 (enExample) |
| CO (1) | CO2020013468A2 (enExample) |
| IL (1) | IL277404A (enExample) |
| MX (1) | MX2020010323A (enExample) |
| PE (1) | PE20212132A1 (enExample) |
| PH (1) | PH12020500664A1 (enExample) |
| SG (1) | SG11202008897SA (enExample) |
| TW (1) | TWI833742B (enExample) |
| WO (1) | WO2019195136A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7477457B2 (ja) | 2018-04-03 | 2024-05-01 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Ｃ３結合薬及びその使用方法 |
| WO2021226442A2 (en) | 2020-05-08 | 2021-11-11 | Ngm Biopharmaceuticals, Inc. | Therapeutic uses of c3-binding agents |
| EP4213808A4 (en) * | 2020-09-21 | 2024-05-22 | Apellis Pharmaceuticals, Inc. | Methods of treating eye disorders |
| WO2022171771A1 (en) * | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| CR20240265A (es) | 2021-12-22 | 2024-10-16 | Boehringer Ingelheim Int | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares |
| WO2024086555A1 (en) * | 2022-10-17 | 2024-04-25 | Ngm Biopharmaceuticals, Inc. | Uses of anti-c3 antibodies |
| CN117447601B (zh) * | 2023-12-22 | 2024-03-08 | 北京索莱宝科技有限公司 | 猪IgM的抗体、抗体组合物及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01002580A (es) * | 1998-09-10 | 2002-04-08 | Univ Virginia | Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas. |
| WO2004031240A1 (en) * | 2002-10-04 | 2004-04-15 | Stichting Sanquin Bloedvoorziening | Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| EP1558645B1 (en) * | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| US20090004183A1 (en) | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| CA2593846A1 (en) | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| SG10201804008UA (en) | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| HUE026001T2 (en) | 2007-02-05 | 2016-04-28 | Apellis Pharmaceuticals Inc | Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system |
| US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| US9745367B2 (en) | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| RU2473563C2 (ru) | 2007-06-07 | 2013-01-27 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| RU2548807C2 (ru) | 2009-05-20 | 2015-04-20 | Торэй Индастриз, Инк. | Пептиды, проникающие в клетку |
| WO2010135717A2 (en) | 2009-05-21 | 2010-11-25 | Potentia Pharmaceuticals, Inc. | Complement assays and uses thereof |
| US20130177567A1 (en) | 2010-05-18 | 2013-07-11 | Sydansk Universitet | Novel c3c epitope, antibodies binding thereto, and use thereof |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| CA2869477C (en) * | 2012-04-03 | 2020-06-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor c3 antibodies and uses thereof |
| AU2014370404A1 (en) | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| CN116059378A (zh) * | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| WO2017048466A1 (en) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Compositions and methods for delivering biotherapeutics |
| US11903994B2 (en) | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| JP2020528082A (ja) | 2017-07-17 | 2020-09-17 | ロイズマン，キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
| JP7477457B2 (ja) | 2018-04-03 | 2024-05-01 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Ｃ３結合薬及びその使用方法 |
-
2019
- 2019-04-01 JP JP2020554097A patent/JP7477457B2/ja active Active
- 2019-04-01 WO PCT/US2019/025123 patent/WO2019195136A1/en not_active Ceased
- 2019-04-01 KR KR1020207030405A patent/KR20200138290A/ko active Pending
- 2019-04-01 BR BR112020019907-9A patent/BR112020019907A2/pt unknown
- 2019-04-01 CN CN201980027315.6A patent/CN112105638A/zh active Pending
- 2019-04-01 EP EP19725880.9A patent/EP3790897A1/en not_active Withdrawn
- 2019-04-01 AU AU2019248557A patent/AU2019248557A1/en not_active Abandoned
- 2019-04-01 US US16/371,684 patent/US11136381B2/en active Active
- 2019-04-01 TW TW108111549A patent/TWI833742B/zh active
- 2019-04-01 AR ARP190100853A patent/AR117565A1/es unknown
- 2019-04-01 CA CA3093356A patent/CA3093356A1/en active Pending
- 2019-04-01 SG SG11202008897SA patent/SG11202008897SA/en unknown
- 2019-04-01 MX MX2020010323A patent/MX2020010323A/es unknown
- 2019-04-01 PE PE2020001505A patent/PE20212132A1/es unknown
-
2020
- 2020-09-16 IL IL277404A patent/IL277404A/en unknown
- 2020-09-29 CL CL2020002522A patent/CL2020002522A1/es unknown
- 2020-10-01 PH PH12020500664A patent/PH12020500664A1/en unknown
- 2020-10-26 CO CONC2020/0013468A patent/CO2020013468A2/es unknown
-
2021
- 2021-08-02 CL CL2021002039A patent/CL2021002039A1/es unknown
- 2021-08-19 US US17/406,991 patent/US11767359B2/en active Active
-
2023
- 2023-08-10 US US18/447,741 patent/US20230382985A1/en not_active Abandoned
-
2024
- 2024-02-13 JP JP2024019502A patent/JP2024056851A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11767359B2 (en) | 2023-09-26 |
| US20190322730A1 (en) | 2019-10-24 |
| TW202003559A (zh) | 2020-01-16 |
| CL2020002522A1 (es) | 2021-02-26 |
| RU2020135712A (ru) | 2022-05-04 |
| JP7477457B2 (ja) | 2024-05-01 |
| US11136381B2 (en) | 2021-10-05 |
| US20230382985A1 (en) | 2023-11-30 |
| PH12020500664A1 (en) | 2021-06-07 |
| MX2020010323A (es) | 2021-01-08 |
| BR112020019907A2 (pt) | 2021-01-05 |
| JP2021520195A (ja) | 2021-08-19 |
| EP3790897A1 (en) | 2021-03-17 |
| AR117565A1 (es) | 2021-08-18 |
| SG11202008897SA (en) | 2020-10-29 |
| JP2024056851A (ja) | 2024-04-23 |
| KR20200138290A (ko) | 2020-12-09 |
| IL277404A (en) | 2020-11-30 |
| CN112105638A (zh) | 2020-12-18 |
| US20220119508A1 (en) | 2022-04-21 |
| TWI833742B (zh) | 2024-03-01 |
| AU2019248557A1 (en) | 2020-09-24 |
| PE20212132A1 (es) | 2021-11-05 |
| CA3093356A1 (en) | 2019-10-10 |
| WO2019195136A1 (en) | 2019-10-10 |
| CL2021002039A1 (es) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013468A2 (es) | Agentes de unión a c3 y métodos para su uso | |
| CL2020003031A1 (es) | Agentes aglutinantes del psma y usos de estos. | |
| ECSP21026339A (es) | Anticuerpos antihlag, composiciones que comprenden anticuerpos antihlag y métodos de uso de anticuerpos antihlag | |
| CO2022008272A2 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
| CO2021013279A2 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| CL2021003343A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3. | |
| CL2022003004A1 (es) | Agentes de unión a ilt y métodos para su uso | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| CO2018000992A2 (es) | Anticuerpos anti-pd-1 novedosos | |
| MX2022015258A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
| MX2020004561A (es) | Anticuerpos biespecificos que se unen a alk-1 y bmpr-2. | |
| CL2021000316A1 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
| CL2016003056A1 (es) | Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer. | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| MX2017006626A (es) | Cadenas ligeras comunes y metodos de uso. | |
| CO2022018537A2 (es) | Agentes de unión a lair-1 y métodos para su uso | |
| CL2020001629A1 (es) | Anticuerpos de unión a hla-a2/wt1. | |
| MX2023010076A (es) | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| CL2020003447A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
| PE20220297A1 (es) | Neutralizacion del virus chikungunya mediada por anticuerpos | |
| AR093620A1 (es) | Anticuerpos bmp-6 | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso |